0001209191-23-024227.txt : 20230413
0001209191-23-024227.hdr.sgml : 20230413
20230413171318
ACCESSION NUMBER: 0001209191-23-024227
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230411
FILED AS OF DATE: 20230413
DATE AS OF CHANGE: 20230413
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ZANTE GREG
CENTRAL INDEX KEY: 0001264949
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 23819113
MAIL ADDRESS:
STREET 1: C/O SANGAMO BIOSCIENCES, INC STE-A-100
STREET 2: POINT RICHMOND TECH, 501 CANAL BLVD,
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-11
0
0001607678
Viking Therapeutics, Inc.
VKTX
0001264949
ZANTE GREG
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
0
Common Stock, par value $0.00001 per share
2023-04-11
4
M
0
3242
7.77
A
152521
D
Common Stock, par value $0.00001 per share
2023-04-11
4
M
0
8500
4.68
A
161021
D
Common Stock, par value $0.00001 per share
2023-04-11
4
M
0
30000
4.88
A
191021
D
Common Stock, par value $0.00001 per share
2023-04-11
4
M
0
14553
5.80
A
205574
D
Common Stock, par value $0.00001 per share
2023-04-11
4
S
0
56295
18.0037
D
149279
D
Common Stock, par value $0.00001 per share
2023-04-12
4
M
0
37447
5.80
A
186726
D
Common Stock, par value $0.00001 per share
2023-04-12
4
M
0
4097
7.77
A
190823
D
Common Stock, par value $0.00001 per share
2023-04-12
4
S
0
41544
18.00
D
149279
D
Stock Option (right to buy)
7.77
2023-04-11
4
M
0
3242
0.00
D
2021-01-03
2030-01-03
Common Stock
3242
16847
D
Stock Option (right to buy
4.68
2023-04-11
4
M
0
8500
0.00
D
2021-03-31
2030-03-31
Common Stock
8500
8500
D
Stock Option (right to buy
4.88
2023-04-11
4
M
0
30000
0.00
D
2023-01-03
2032-01-03
Common Stock
30000
90000
D
Stock Option (right to buy
5.80
2023-04-11
4
M
0
14553
0.00
D
2022-01-04
2031-01-04
Common Stock
14553
63447
D
Stock Option (right to buy
5.80
2023-04-12
4
M
0
37447
0.00
D
2022-01-04
2031-01-04
Common Stock
37447
26000
D
Stock Option (right to buy)
7.77
2023-04-12
4
M
0
4097
0.00
D
2021-01-03
2030-01-03
Common Stock
4097
12750
D
The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person.
25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date.
The Form 4 filed by the Reporting Person on April 3, 2023 reporting, among other things, the exercise of 30,911 shares subject to this option on April 3, 2023 inadvertently indicated that there were 0 shares remaining subject to this option after such exercise. That Form 4 should have reflected that there were 20,089 shares remaining subject to this option after such exercise and the balance has been adjusted accordingly in this Form 4.
One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date.
/s/ Michael Morneau as Attorney-in-Fact
2023-04-13